This article is more than 5 years old. Information may no longer be current.
Cardiology Today's Intervention Top 5 stories posted in December
Cardiology Today’s Intervention compiled a list of the top 5 stories posted to Healio.com/Intervention in December.
This month, readers were most interested in hospital readmission rates after PAD revascularization, optimal endovascular strategies for infrapopliteal lesions, the results of the PREMIUM trial, new guidelines for patients with abdominal aortic aneurysms, the IDE approval of a percutaneous femoropopliteal bypass system and much more.
Hospital readmission rates high after revascularization for PAD
More than one in six patients undergoing revascularization for peripheral artery disease were readmitted to the hospital within 30 days of the procedure, according to new data published in Annals of Internal Medicine.
These unplanned readmissions were also associated with increased mortality and high costs.
Optimal endovascular strategy for infrapopliteal lesions remains unclear
Although drug-coated balloons show some promise as a treatment option for patients with infrapopliteal lesions, questions linger about their efficacy in this population, experts noted during a debate at TCT 2017.
“The topic is controversial, but I do believe there is hope for the future,” Bryan T. Fisher Sr., MD, chief of vascular surgery and co-director of the limb Preservation Center at TriStar Centennial Medical Center, Nashville, Tennessee, said.
PREMIUM: PFO closure fails to reduce migraine attacks, adverse events
Patients with migraine who were treated with medical therapy and patent foramen ovale closure did not have a reduction in responder rate compared with those who were treated with medical therapy and a sham procedure, according to a study published in the Journal of the American College of Cardiology.
New guideline endorses endovascular repair for ruptured AAA
The new Society for Vascular Surgery guideline on care of patients with abdominal aortic aneurysms recommends endovascular repair over surgery for ruptured AAA if it is anatomically feasible.
The guideline, the first in 9 years, also recommends AAA repair procedures be limited to centers that meet standards for quality and volume, and that the Society for Vascular Surgery (SVS) Vascular Quality Initiative mortality risk score be used when making decisions about AAA repair.
Percutaneous femoropopliteal bypass system receives IDE approval
PQ Bypass Inc. announced it has received conditional approval of its investigational device exemption from the FDA to begin the first-ever pivotal trial for percutaneous femoropopliteal bypass.
The DETOUR II clinical trial is designed to evaluate the safety and efficacy of the Detour system, which performs revascularization via modular stent graft bypass using the femoral vein as a conduit, in up to 292 patients with lower limb ischemia due to blockages larger than 15 cm in the superficial femoral artery due to PAD.